Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of vehicle or drug treatment on gene expression in BxPC3 cell line

ABSTRACT: Effect of vehicle or drug treatment on gene expression in BxPC3 cell line

PROVIDER: PRJNA1160227 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30644650_1.fastq.gz	Fastqsanger.gz
	SRR30644650_2.fastq.gz	Fastqsanger.gz
	SRR30644651_1.fastq.gz	Fastqsanger.gz
	SRR30644651_2.fastq.gz	Fastqsanger.gz
	SRR30644652_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Effect of vehicle or drug treatment on gene expression in BxPC3 cell line

Project description:To investigate the effect of mutant p53 Y220C acetylation in gene expression, we treated BxPC3 (p53Y220C/-) cell lines with either DMSO, or PK9328 or MS172.

2024-09-26 | GSE277017 | GEO

DDR1 knockdown in BXPC3 cell line

Project description:Examination of effect of stable DDR1 knockdown by shRNA on transcriptional profile in BXPC3 cell line to understand role of DDR1 in tumorigenesis. Transcriptional profiles of parental BXPC3 cell line was compared to BXPC3 cells stably transfected with non-target shRNA or DDR1 shRNA, N=3 for each condition.

2014-05-01 | E-GEOD-39207 | biostudies-arrayexpress

DDR1 knockdown in BXPC3 cell line

Project description:Examination of effect of stable DDR1 knockdown by shRNA on transcriptional profile in BXPC3 cell line to understand role of DDR1 in tumorigenesis.

2014-05-01 | GSE39207 | GEO

miRNA expression data from pancreatic ductal adenocarcinoma (PDAC) cell line BxPC3 and its cisplatin-resistant derivative BxPC3-R

Project description:Differential expression of miRNAs between parental and cisplatin-resistant PDAC cells was analyzed to elucidate the role of miRNAs in the acquired resistance of pancreatic cancer cells to cisplatin. Cisplatin-resistant BxPC3-R cells were developed from the parental BxPC3 cell line by culturing them in medium with step-wise increasing concentration of cisplatin.

2016-05-01 | GSE79506 | GEO

mRNA-seq of gemcitabine resistant pancreatic cancer cell line subclones derived from BxPC3

Project description:We generated gemcitabine resistant subclones from the human pancreatic cancer cell line BxPC3 using chronic low dose exposure to gemcitabine. Three gemcitabine resistant subclones (BxGR-80C, BxGR-120C and BxGR-360C) were sequenced in addition to BxPC3 cells.

2021-12-21 | E-MTAB-11186 | biostudies-arrayexpress

Expression data from pancreatic ductal adenocarcinoma (PDAC) cell lines AsPC1, BxPC3 and their cisplatin-resistant derivatives AsPC1-R and BxPC3-R

Project description:Cisplatin is a broad-spectrum anticancer drug, which is estimated to be administered to 40-80% of patients undergoing chemotherapy. However, its clinical utility is often limited due to factors that include acquired resistance of cancer cells to cisplatin. Because cisplatin is currently evaluated as a prospective agent for combined chemotherapy of pancreatic ductal adenocarcinoma (PDAC), we have investigated mechanisms involved in the acquired resistance of PDAC cells to cisplatin using gene expression study of two different parental-resistant pairs of PDAC cell lines. We have developed cisplatin-resistant cell lines AsPC1-R and BxPC3-R from their parental PDAC cell lines AsPC1 and BxPC3, respectively, by culturing them in medium with step-wise increasing concentration of cisplatin. Parental and resistant pairs of PDAC cells were analyzed by whole-transcript gene expression analysis.

2015-11-30 | GSE73978 | GEO

Effect of ANO1 overexpression and/or oncogenic KRAS on gene expression of BxPC3 cells

Project description:RNA seq analysis was performed to assess the transcriptional profiles of BxPC3 cells with different status of ANO1 and KRAS.

2023-03-31 | GSE202825 | GEO

Expression data of U87 MG glioblastoma cells with vehicle or with 30nM Panobinostat treatment for 3 weeks

Project description:Low dose of HDAC inhibitor (Panobinostat) treatment causes U87 cells to become resistant to the drug. Gene expression of the resistant cell line is altered comparing to the vehicle control.

2019-09-18 | GSE103961 | GEO

mRNA-seq of gemcitabine resistant pancreatic cancer cell line subclones derived from BxPC3

Project description:mRNA-seq of gemcitabine resistant pancreatic cancer cell line subclones derived from BxPC3

| PRJEB48965 | ENA

Deep sequencing of an AML cell line treated with vehicle control, BETi, MDM2i, or a drug combination

Project description:Deep sequencing of an AML cell line treated with vehicle control, BETi, MDM2i, or a drug combination

| PRJNA546589 | ENA